Mirae Asset Global Investments Co., Ltd. Intellia Therapeutics, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $30.9 Billion
- Q3 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 4,150 shares of NTLA stock, worth $36,105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,150
Previous 4,001
3.72%
Holding current value
$36,105
Previous $37,000
91.89%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding NTLA
# of Institutions
343Shares Held
103MCall Options Held
3.16MPut Options Held
1.56M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$104 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$96.1 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$83.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.02MShares$52.4 Million0.01% of portfolio
-
Contrarius Group Holdings LTD Hamilton, D05.89MShares$51.2 Million4.6% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $661M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...